What is the fair value of Ascendis Pharma AS (NASDAQ-ASND) stock?

The current fair value estimate for Ascendis Pharma AS (NASDAQ-ASND) is $239.36. This implies an estimated downside of 1.6% versus the current market price.

Is Ascendis Pharma AS (NASDAQ-ASND) undervalued or overvalued?

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

What is the analyst price target for NASDAQ-ASND stock?

The available analyst price target for Ascendis Pharma AS (NASDAQ-ASND) is $306.44. The analyst target implies estimated upside of 25.9%.

How is the financial health of Ascendis Pharma AS?

The current financial health read for Ascendis Pharma AS (NASDAQ-ASND) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Ascendis Pharma AS's next earnings date?

The next earnings date currently listed for Ascendis Pharma AS (NASDAQ-ASND) is November 11, 2026.

Does Ascendis Pharma AS (NASDAQ-ASND) pay dividends?

The latest available data indicates no current dividend yield for Ascendis Pharma AS (NASDAQ-ASND).

What is the P/E ratio for Ascendis Pharma AS (NASDAQ-ASND)?

The current P/E ratio listed for Ascendis Pharma AS (NASDAQ-ASND) is 19.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Ascendis Pharma AS?

The current market capitalization listed for Ascendis Pharma AS is 15.983 B.

What is the enterprise value of Ascendis Pharma AS?

The current enterprise value listed for Ascendis Pharma AS is 15.882 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Ascendis Pharma AS?

The ticker symbol for Ascendis Pharma AS is NASDAQ-ASND, and the stock is listed on NASDAQ.

Where is Ascendis Pharma AS (NASDAQ-ASND) listed?

Ascendis Pharma AS (NASDAQ-ASND) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Ascendis Pharma AS?

The current debt-to-total-capital ratio listed for Ascendis Pharma AS is 3.1%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Ascendis Pharma AS?

The free float listed for Ascendis Pharma AS is 100.0%. Free float helps investors understand how much of the share base is available for public trading.

Ascendis Pharma AS (ASND) Fair Value & Stock Analysis

Ascendis Pharma AS (ASND)

Ascendis Pharma A/S is a biopharmaceutical company focused on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and other international markets. Its commercial portfolio includes SKYTROFA, used to treat pediatric patients with growth hormone deficiency, and YORVIPATH, a once-daily subcutaneous treatment for adults with chronic hypoparathyroidism. The company also has three endocrinology rare disease candidates in clinical development and is advancing oncology therapeutic candidates. Founded in 2006 and based in Hellerup, Denmark, Ascendis Pharma’s common stock is listed on NASDAQ in ADR form under the ticker ASND.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-ASND	$239.36	-1.6% Downside	Fair	$306.44	25.9% Upside	Undervalued	Great	0.0%	November 11, 2026	19.2x	9.9x	13.6x	15.983 B	15.882 B	3.1%	100.0%	5.8	45.2%